BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of “Moderate Buy” from Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $251.70.

BGNE has been the topic of a number of research analyst reports. Sanford C. Bernstein dropped their price objective on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a report on Wednesday, March 27th. Bank of America lowered their price target on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a report on Monday, April 8th. Guggenheim lowered their price target on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. upped their price target on shares of BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th.

BeiGene Stock Performance

Shares of BGNE stock opened at $131.96 on Friday. The business’s fifty day simple moving average is $155.65 and its 200-day simple moving average is $168.86. The company has a market cap of $12.62 billion, a PE ratio of -15.52 and a beta of 0.61. The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. BeiGene has a 12-month low of $131.28 and a 12-month high of $266.67.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Monday, February 26th. The company reported ($3.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.08. The firm had revenue of $634.40 million for the quarter, compared to analyst estimates of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business’s quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($4.29) earnings per share. Analysts expect that BeiGene will post -8.87 earnings per share for the current fiscal year.

Insider Transactions at BeiGene

In related news, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Oyler sold 26,716 shares of the stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the sale, the chief executive officer now owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. Insiders have sold a total of 64,781 shares of company stock valued at $10,222,381 in the last ninety days. 7.40% of the stock is currently owned by corporate insiders.

Institutional Trading of BeiGene

Hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its holdings in BeiGene by 26.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock valued at $54,000 after acquiring an additional 51 shares during the last quarter. Toronto Dominion Bank increased its holdings in shares of BeiGene by 166.4% during the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after buying an additional 208 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its holdings in shares of BeiGene by 20.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock worth $80,000 after buying an additional 76 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of BeiGene during the 4th quarter worth approximately $98,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of BeiGene by 73.5% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 694 shares of the company’s stock worth $125,000 after buying an additional 294 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.